Need more? Try out  Advanced Search (20+ criteria)»

logo

Last Update

This profile was last updated on 12/5/2016 and contains contributions from the  Zoominfo Community.

is this you? Claim your profile.

Wrong Hsiao Lieu?

Hsiao D. Lieu

Director

Portola Pharmaceuticals , Inc.

HQ Phone:  (650) 246-7000

Email: h***@***.com

GET ZOOMINFO GROW

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions.

I agree to the  Terms of Service and  Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

THANK YOU FOR DOWNLOADING!

computers
  • 1.Download
    ZoomInfo Grow
    v sign
  • 2.Run Installation
    Wizard
  • 3.Check your inbox to
    Sign in to ZoomInfo Grow

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Portola Pharmaceuticals , Inc.

270 E. Grand Avenue

South San Francisco, California,94080

United States

Company Description

Portola Pharmaceuticals is a biopharmaceutical company developing product candidates that could significantly advance the fields of thrombosis and other hematologic diseases. The Company is advancing its three programs using novel biomarker and genetic approac...more

Background Information

Employment History

Adjunct Assistant Clinical Professor of Medicine, Cardiology Division

University of California , San Francisco


Senior Director, Clinical Development

Portola Pharmaceuticals , Inc.


Researcher

J. David Gladstone Institute of Cardiovascular Disease at the University of California at San Francisco


Affiliations

American College of Cardiology

Fellow


Education

M.D.

Albert Einstein College


M.D.

Albert Einstein College of Medicine


Web References(28 Total References)


www.sec.gov

Hsiao Lieu
Hsiao D. Lieu, M.D., F.A.C.C. has been the Company’s Vice President of Clinical Research since March 2008. Dr. Lieu has over 13 years of experience in the biopharmaceutical/biotech industry including academic medicine (cardiology), molecular cardiology research, translational and clinical drug development including execution of large multinational Phase III clinical trials and responsibility for interactions with regulatory authorities and key opinion leaders in the U.S., Canada, and Europe. From 2006 to 2008, Dr. Lieu was Director of Clinical Development for Portola Pharmaceuticals, Inc. From 2003 to 2006 Dr. Lieu worked at CV Therapeutics, Inc., where he served as Director, Clinical Research and Development. Dr. Lieu also worked as a researcher at the J. David Gladstone Institute of Cardiovascular Disease at the University of California at San Francisco (“UCSF”) from 2001 to 2003 where he conducted molecular cardiology research. Dr. Lieu currently serves as an Adjunct Assistant Clinical Professor of Medicine, Cardiology Division at UCSF. Dr. Lieu completed his clinical cardiology fellowship at UCSF and his residency in internal medicine at Columbia University. He received his M.D. from the Albert Einstein College of Medicine with distinction in molecular biology research, and his B.A. from New York University. Dr. Lieu is a Fellow of the American College of Cardiology.


www.prnewswire.com

Hsiao Dee Lieu, M.D., F.A.C.C. Named VP of Clinical Research of Nile Therapeutics appointment of Hsiao Dee Lieu, M.D., F.A.C.C. as its Vice President of Clinical Research. "I am delighted to welcome Dr. Lieu to Nile.Dr. Lieu has extensive Dr. Lieu has significant translational experience, which includes molecular cardiology research through clinical execution of large multinational Phase III clinical trials.Prior to joining Nile, Dr. Lieu served as Director of Clinical Development for Portola Pharmaceuticals, Inc., where he led the global development of a large ADP antagonist program in acute coronary syndrome.In this role, Dr. Lieu was responsible for the overall clinical development plan of intravenous and oral molecules from early- to late-stage development.He led the development of trial designs (Phase I to Phase III) with successful execution of Phase I and II trials. He has managed interactions with regulatory authorities and key opinion leaders in the U.S., Canada, and Europe. Before joining Portola, Dr. Lieu worked at CV Therapeutics, Inc. (CVTX), where he served as Director, Clinical Research and Development.In this role, he led the clinical development program for regadenoson, which included two large multinational successful Phase III trials.Dr. Lieu also worked as a researcher at the J. David Gladstone Institute of Cardiovascular Disease at the University of California at San Francisco (UCSF) conducting molecular cardiology research in gene manipulation and induction of cardiomyopathy and atherosclerosis regression. Dr. Lieu currently serves as Assistant Clinical Professor of Medicine, Cardiology Division at UCSF.Dr. Lieu completed his clinical cardiology fellowship at UCSF and his residency in internal medicine at Columbia University.He received his M.D. from the Albert Einstein College of


www.baacnetwork.org

Speaker: Hsiao D. Lieu, MD., FACC (Senior Director, Clinical Development, Portola Pharmaceuticals).


scr.zacks.com [cached]

We note that Nile's Executive Chairman, Richard B. Brewer, President and CEO, Joshua A. Karam, CFO, Daron Evans, and VP of Clinical Development, Hsiao Lieu, MD, all participated in the deal, ponying up $110,000 of their own money.


scr.zacks.com [cached]

On March 26, 2012, Dr. Hsiao D. Lieu, MD, FACC, Nile Therapeutics' (OTC Markets:NLTX) Vice President of Clinical Research, presented the results from the company's phase 1 safety and pharmacokinetic / pharmacodynamic (PK/PD) clinical trial with cenderitide at the 61th annual Scientific Session of the American College of Cardiology (ACC) meeting held in Chicago, IL.
The poster presentation ( board #628) was titled, "Initial Experience with Subcutaneous Infusion of Cenderitide in Patients with Chronic Heart Failure."


Similar Profiles

city

Browse ZoomInfo's Business
Contact Directory by City

city

Browse ZoomInfo's
Business People Directory

city

Browse ZoomInfo's
Advanced Company Directory